Yuyu Pharma, Inc. (000227.KS)
KRW 9750.0
(-0.41%)
KRW 9750.0
(-0.41%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 44.15 Billion KRW | 10.85% |
| 2022 | 39.83 Billion KRW | 57.91% |
| 2021 | 25.22 Billion KRW | 6.49% |
| 2020 | 23.68 Billion KRW | 39.22% |
| 2019 | 17.01 Billion KRW | 8.97% |
| 2018 | 15.61 Billion KRW | -20.3% |
| 2017 | 19.59 Billion KRW | 39.62% |
| 2016 | 14.03 Billion KRW | 9.73% |
| 2015 | 12.78 Billion KRW | 55.51% |
| 2014 | 8.22 Billion KRW | 15.87% |
| 2013 | 7.09 Billion KRW | -12.66% |
| 2012 | 8.12 Billion KRW | 48.27% |
| 2011 | 5.48 Billion KRW | 2.32% |
| 2010 | 5.35 Billion KRW | -10.49% |
| 2009 | 5.98 Billion KRW | -43.47% |
| 2008 | 10.58 Billion KRW | -17.82% |
| 2007 | 12.88 Billion KRW | 29.83% |
| 2006 | 9.92 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 43.56 Billion KRW | -1.32% |
| 2024 Q2 | 43.25 Billion KRW | -0.71% |
| 2023 FY | 44.15 Billion KRW | 10.85% |
| 2023 Q3 | 43.25 Billion KRW | -11.73% |
| 2023 Q2 | 49 Billion KRW | 8.68% |
| 2023 Q4 | 44.15 Billion KRW | 2.08% |
| 2023 Q1 | 45.09 Billion KRW | 13.2% |
| 2022 Q4 | 39.83 Billion KRW | 23.52% |
| 2022 FY | 39.83 Billion KRW | 57.91% |
| 2022 Q3 | 32.24 Billion KRW | 11.9% |
| 2022 Q2 | 28.81 Billion KRW | 16.41% |
| 2022 Q1 | 24.75 Billion KRW | -1.86% |
| 2021 FY | 25.22 Billion KRW | 6.49% |
| 2021 Q2 | 24.04 Billion KRW | 0.1% |
| 2021 Q3 | 26.14 Billion KRW | 8.72% |
| 2021 Q4 | 25.22 Billion KRW | -3.52% |
| 2021 Q1 | 24.02 Billion KRW | 1.41% |
| 2020 Q2 | 21.09 Billion KRW | 19.27% |
| 2020 FY | 23.68 Billion KRW | 39.22% |
| 2020 Q3 | 23.9 Billion KRW | 13.32% |
| 2020 Q1 | 17.68 Billion KRW | 3.96% |
| 2020 Q4 | 23.68 Billion KRW | -0.92% |
| 2019 Q4 | 17.01 Billion KRW | 5.25% |
| 2019 Q3 | 16.16 Billion KRW | -0.21% |
| 2019 FY | 17.01 Billion KRW | 8.97% |
| 2019 Q1 | 15.89 Billion KRW | 1.76% |
| 2019 Q2 | 16.2 Billion KRW | 1.95% |
| 2018 Q2 | 16.85 Billion KRW | -6.95% |
| 2018 FY | 15.61 Billion KRW | -20.3% |
| 2018 Q4 | 15.61 Billion KRW | -7.9% |
| 2018 Q3 | 16.95 Billion KRW | 0.61% |
| 2018 Q1 | 18.11 Billion KRW | 0.0% |
| 2017 FY | 19.59 Billion KRW | 39.62% |
| 2017 Q1 | 14.03 Billion KRW | -10.1% |
| 2017 Q2 | 14.87 Billion KRW | 6.02% |
| 2017 Q3 | 18.15 Billion KRW | 22.01% |
| 2016 Q4 | 15.6 Billion KRW | 15.76% |
| 2016 Q3 | 13.48 Billion KRW | 3.1% |
| 2016 Q2 | 13.07 Billion KRW | 2.26% |
| 2016 Q1 | 12.78 Billion KRW | -8.59% |
| 2016 FY | 14.03 Billion KRW | 9.73% |
| 2015 Q1 | 8.22 Billion KRW | 6.16% |
| 2015 FY | 12.78 Billion KRW | 55.51% |
| 2015 Q4 | 13.99 Billion KRW | 17.34% |
| 2015 Q3 | 11.92 Billion KRW | 13.06% |
| 2015 Q2 | 10.54 Billion KRW | 28.23% |
| 2014 Q4 | 7.74 Billion KRW | 9.37% |
| 2014 Q3 | 7.08 Billion KRW | 4.1% |
| 2014 Q2 | 6.8 Billion KRW | -4.14% |
| 2014 Q1 | 7.09 Billion KRW | 3.97% |
| 2014 FY | 8.22 Billion KRW | 15.87% |
| 2013 Q3 | 8.58 Billion KRW | -1.84% |
| 2013 Q2 | 8.75 Billion KRW | 7.68% |
| 2013 FY | 7.09 Billion KRW | -12.66% |
| 2013 Q1 | 8.12 Billion KRW | 0.0% |
| 2013 Q4 | 6.82 Billion KRW | -20.53% |
| 2012 FY | 8.12 Billion KRW | 48.27% |
| 2011 Q4 | 6.03 Billion KRW | 2.03% |
| 2011 Q2 | 5.75 Billion KRW | 7.44% |
| 2011 Q3 | 5.91 Billion KRW | 2.73% |
| 2011 Q1 | 5.35 Billion KRW | 0.47% |
| 2011 FY | 5.48 Billion KRW | 2.32% |
| 2010 Q3 | 6.41 Billion KRW | 12.28% |
| 2010 Q2 | 5.71 Billion KRW | -4.54% |
| 2010 Q1 | 5.98 Billion KRW | -18.35% |
| 2010 Q4 | 5.33 Billion KRW | -16.89% |
| 2010 FY | 5.35 Billion KRW | -10.49% |
| 2009 Q4 | 7.32 Billion KRW | -20.67% |
| 2009 Q2 | 9.73 Billion KRW | -8.07% |
| 2009 Q3 | 9.23 Billion KRW | -5.06% |
| 2009 FY | 5.98 Billion KRW | -43.47% |
| 2009 Q1 | 10.58 Billion KRW | -12.42% |
| 2008 Q3 | 11.98 Billion KRW | 1.72% |
| 2008 Q1 | 12.88 Billion KRW | 10.23% |
| 2008 FY | 10.58 Billion KRW | -17.82% |
| 2008 Q4 | 12.08 Billion KRW | 0.86% |
| 2008 Q2 | 11.78 Billion KRW | -8.53% |
| 2007 Q2 | 11.34 Billion KRW | 0.0% |
| 2007 Q4 | 11.68 Billion KRW | -2.96% |
| 2007 Q3 | 12.04 Billion KRW | 6.11% |
| 2007 FY | 12.88 Billion KRW | 29.83% |
| 2006 FY | 9.92 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 62.536% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 51.57% |
| HANDOK Inc. | 94.46 Billion KRW | 53.261% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -107.842% |
| Yuhan Corporation | 284.75 Billion KRW | 84.495% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 62.04% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -171.561% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 84.713% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -36.339% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 28.469% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -126.688% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -45.812% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 8.677% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 0.0% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -41.329% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -25.516% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | 8.261% |
| JW Holdings Corporation | 147.58 Billion KRW | 70.084% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 47.825% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 83.111% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 58.383% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 18.12% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -63.539% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -35.805% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 59.777% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 0.0% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 76.595% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 81.721% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 58.383% |
| Yuhan Corporation | 284.75 Billion KRW | 84.495% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 64.757% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 28.771% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 83.008% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 58.383% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 44.534% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 10.154% |
| CKD Bio Corp. | 69.08 Billion KRW | 36.088% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 57.982% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 37.547% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 18.324% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 18.12% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 77.331% |
| Boryung Corporation | 189.8 Billion KRW | 76.738% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 22.311% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 28.469% |
| JW Lifescience Corporation | 23.39 Billion KRW | -88.696% |